AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: CELU
Report Date: 2026-05-11
Full Report: https://amaly.io/stock/CELU

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Celularity Inc. (CELU), a biotechnology company developing cellular therapies, exhibits significant Shariah non-compliance primarily due to excessive debt levels (144.96% of market cap) and high interest income (36.03% of revenue). While its core business in regenerative medicine aligns with Islamic principles of health advancement, financial screening fails across AAOIFI, MSCI, and S&P standards. No inclusion in major Shariah indices confirms non-compliance status. Purification at 36.03% is required for any dividends, but structural debt issues pose ongoing risks. Investors should monitor for refinancing toward Islamic structures.

Primary Compliance Concerns:
- debtRatio: 144.96% (threshold: 30%)
- interestIncomeRatio: 36.03% (threshold: 5%)

Purification Requirement: 36.03%
Index Inclusion: Not included in any major Shariah indices: S&P Dow Jones, MSCI, FTSE, or DJIM

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 145.0%
Liquidity Ratio: 0.0%
Interest Income Ratio: 36.0%
Purification Required: 36.03%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-24T12:00:00Z

---
Full interactive report: https://amaly.io/stock/CELU
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.